How much does the domestic version of lapatinib cost? Is it worth choosing?

As of now, there is no domestically produced generic version of Lapatinib in the Chinese market, so it is still too early to talk about its domestic price. At this stage, the original version produced by GlaxoSmithKline (GSK) is mainly sold on the market. As a globally recognized targeted drug for HER2-positive breast cancer, lapatinib’s patent protection and technical threshold are relatively high, so domestic pharmaceutical companies have not yet been able to imitate or produce substitutes for the drug.

Since there are no domestic generic versions, patients can only use imported original drugs when choosing, which means there is a lack of competitive products at the price level. The current price of lapatinib is relatively high. The common specification is 0.25g*70 tablets. The market price per box is generally more than RMB 5,000 to 6,000 yuan, and the monthly medication cost may reach 10,000 yuan. For patients undergoing long-term treatment, this undoubtedly constitutes a greater economic burden. Therefore, although the clinical efficacy of lapatinib has been fully recognized, economic factors are still a key consideration for many patients when choosing medication.

Whether it is worth choosing lapatinib mainly depends on the patient’s molecular diagnosis results and disease progression. For patients with HER2-positive breast cancer, especially those who are no longer sensitive to or have developed resistance to trastuzumab, lapatinib can be an important alternative treatment option. Its dual-target mechanism of action helps inhibit tumor metastasis and prolong progression-free survival. Although it is more expensive, it can delay tumor progression and improve quality of life in some cases. Therefore, patients should fully communicate with their attending doctors before use, evaluate the clinical value and economic affordability, and pay attention to the possibility of a domestic version being launched in the future, in anticipation of the improvement in treatment accessibility brought about by price reductions.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html